PTC Therapeutics Inc PTCT

NAS: PTCT | ISIN: US69366J2006 17/01/2025

43,84 USD (+1,76%)

(+1,76%) 17/01/2025

Grafiek PTC Therapeutics Inc

Grafiek PTC Therapeutics Inc

1 dag1d 1,76%
1 week1w 4,86%
1 maand1m -3,78%
3 maanden3m 14,05%
6 maanden6m 32,73%
1 jaar1j 60,76%
5 jaar5j -18,07%

PTC Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

28 augustus 2024 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results · Persbericht

30 juli 2024 · PTC Therapeutics Announces Sepiapterin NDA Submission to FDA · Persbericht

25 juli 2024 · PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results · Persbericht

28 juni 2024 · CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review · Persbericht

21 juni 2024 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 juni 2024 · Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients · Persbericht

29 mei 2024 · PTC Therapeutics to Participate at Upcoming Investor Conference · Persbericht

28 mei 2024 · PTC Therapeutics Announces Validation of Sepiapterin European MAA · Persbericht

20 mei 2024 · PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation · Persbericht

Profiel PTC Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ptcbio.com

Hoofdzetel: South Plainfield, New Jersey Verenigde Staten

CEO: Stuart Peltz

Werknemers: 1.467

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe